Breaking News
Investing Pro 0
Cyber Monday Extended SALE: Up to 60% OFF InvestingPro+ CLAIM OFFER

CVS Health raises annual profit view after better-than-expected first quarter

Economy May 04, 2022 10:02AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. CVS Health logo is seen displayed in this illustration taken, May 3, 2022. REUTERS/Dado Ruvic/Illustration/File Photo

By Mrinalika Roy

(Reuters) -CVS Health Corp beat estimates for first-quarter results on Wednesday, helped by strong performance in its retail store operations and insurance unit, encouraging the company to raise annual adjusted profit forecast.

Pharmacy chains like CVS have benefited from distribution of COVID-19 vaccines and tests during the pandemic. However, in February, the company said it expected a big decline in COVID-19 vaccination and testing administered at its stores this year.

The company administered over eight million COVID-19 vaccines at its stores in the quarter, and now expects to administer 18 million vaccines in total in 2022. This is in stark contrast to over 20 million vaccines it administered in the preceding quarter.

COVID-related contribution to retail business is expected to fall 60%-65% this year, Chief Financial Officer Shawn Guertin said during a post-earnings call.

The company also administered fewer COVID tests at its stores than the preceding quarter but said demand for over-the-counter COVID-19 tests was higher which added to its retail segment growth.

Retail segment performance was also driven by inflation of branded drugs and higher prescription volumes.

Same-store sales rose 10.7% in the quarter, as easing coronavirus curbs boosted footfalls.

Falling demand for COVID-19 related products was also offset by membership growth in its healthcare benefits segment, which offers various insurance products and services. The segment saw a 12.8% rise in revenue in the quarter and the company now expects membership increases between 24 million and 24.3 million for the full year.

Morningstar analyst Julie Utterback said CVS turned in a 'stellar' quarterly performance which allowed management to slightly increase its bottom-line outlook for the full year.

On an adjusted basis, CVS earned $2.22 per share, compared with estimates of $2.15.

The company now expects 2022 full-year adjusted profit to be between $8.20 and $8.40 per share, higher than its prior guidance of $8.10 and $8.30 per share.

CVS Health raises annual profit view after better-than-expected first quarter
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email